Zhang XH, Cao MQ, Li XX, Zhang T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J Hepatol 2020; 12(10): 766-774 [PMID: 33200015 DOI: 10.4254/wjh.v12.i10.766]
Corresponding Author of This Article
Ti Zhang, MD, Professor, Surgical Oncologist, Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, No. 24 Binshui Road, Tianjin 300060, China. zhangti@tjmuch.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Oct 27, 2020; 12(10): 766-774 Published online Oct 27, 2020. doi: 10.4254/wjh.v12.i10.766
Apatinib as an alternative therapy for advanced hepatocellular carcinoma
Xi-Hao Zhang, Man-Qing Cao, Xiu-Xiu Li, Ti Zhang
Xi-Hao Zhang, Xiu-Xiu Li, Ti Zhang, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Xi-Hao Zhang, Man-Qing Cao, Xiu-Xiu Li, Ti Zhang, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Tianjin 300060, China
Man-Qing Cao, Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Xiu-Xiu Li, Digestive Department, Shanxi Province Tumor Hospital, Taiyuan 030013, Shanxi Province, China
Ti Zhang, Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Author contributions: Zhang XH, Cao MQ and Li XX contributed to idea and design, literature search, and writing, review, and editing of the manuscript; all authors have read and approve the final manuscript.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ti Zhang, MD, Professor, Surgical Oncologist, Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, No. 24 Binshui Road, Tianjin 300060, China. zhangti@tjmuch.com
Received: February 27, 2020 Peer-review started: February 27, 2020 First decision: April 25, 2020 Revised: June 2, 2020 Accepted: August 15, 2020 Article in press: August 15, 2020 Published online: October 27, 2020 Processing time: 239 Days and 19.6 Hours
Abstract
Angiogenesis plays an important role in the occurrence and development of tumors. Registered tyrosine kinase inhibitors targeting vascular endothelial growth factor reduce angiogenesis. Apatinib, a tyrosine kinase inhibitor, can specifically inhibit vascular endothelial growth factor receptor 2, showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma (HCC). This article intends to review the clinical research and application prospects of apatinib in the field of HCC.
Core Tip: Apatinib, as a tyrosine kinase inhibitor, has a good inhibitory effect on advanced hepatocellular carcinoma (HCC). In this article, we will introduce the role of apatinib in advanced HCC from the aspects of structure and mechanism, pharmacokinetics, preclinical studies, clinical trials, side effects, and combined drug use.
